TheraRadar
← Back
Data updated: May 24, 2026

ANACOR PHARMS INC

Pharma

ANACOR PHARMS INC is a pharmaceutical company focused on Oncology, Infectious Disease, Dermatology. Key products include EUCRISA.

2014
Since
2
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules
Novel Drugs (2016):
1 Novel Approvals

Key Drugs

Top revenue-generating and strategically important drugs approved in the last 15 years. These represent the company's core commercial portfolio.

Recent FDA Approvals

New drug approvals (NDA/BLA) in the last 2 years. Shows novel drugs only, excluding generics and label supplements.

No recent approvals

Therapeutic Areas

Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.

Oncology 57%
0 drugs Phase 3: 3 Phase 2: 6 Phase 1: 7
Infectious Disease 22%
0 drugs Phase 3: 2 Phase 2: 2
Dermatology 11%
1 drugs
Cardiovascular 7%
0 drugs Phase 3: 1
Gastroenterology 2%
0 drugs Phase 1: 1

Pipeline Snapshot

Active clinical trials across all therapeutic areas. Data from ClinicalTrials.gov.

6
Phase 3
8
Phase 2
8
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • EUCRISA leads revenue
  • Drug-level revenue analysis

Trial Catalysts

  • Oncology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling